We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pluripotent Stem Cell Evaluation Agreement Between Roslin Cells and Pfizer for Regenerative Medicine Development
News

Pluripotent Stem Cell Evaluation Agreement Between Roslin Cells and Pfizer for Regenerative Medicine Development

Pluripotent Stem Cell Evaluation Agreement Between Roslin Cells and Pfizer for Regenerative Medicine Development
News

Pluripotent Stem Cell Evaluation Agreement Between Roslin Cells and Pfizer for Regenerative Medicine Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pluripotent Stem Cell Evaluation Agreement Between Roslin Cells and Pfizer for Regenerative Medicine Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Roslin Cells and Pfizer Limited have signed an agreement for Pfizer to evaluate Roslin’s GMP quality Pluripotent Stem Cells (PSC).

The evaluation will allow Pfizer access to Roslin’s Cell lines with a view to assessing the potential for specific clinical therapies.

The agreement is the first time Roslin’s GMP cell lines have been evaluated by one of the major pharmaceutical companies.

Aidan Courtney, Roslin Cells CEO commented ‘We have made a substantial investment in establishing the capability to derive new stem cell lines to the standards required for their use as the starting material for a clinical therapy. They are already being used in our own collaborative research programmes and I am delighted that they will now be evaluated for potential use by Pfizer.’

Commercial terms are confidential and not disclosed.

Advertisement